FDA 483 - Citrogein (Div of GVK Biosciences) - March 13, 2015
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Citrogein (Div of GVK Biosciences), a Clinical Pharmacological Unit in Hyderabad, India, revealed significant issues with data integrity and record-keeping practices. Observations included discrepancies in electronic ECG records, lack of documentation for adverse event evaluations during study wash-out periods, and missing information regarding drug screening assay systems. Additionally, the firm failed to maintain complete correspondence files between the clinical site and the sponsor.
- Person
ID · fb6d2324-28e5-4fde-bd0d-a19519e9f2a8